El-Salhy Magdy, Kristoffersen Anja Bråthen, Valeur Jørgen, Casen Christina, Hatlebakk Jan Gunnar, Gilja Odd Helge, Hausken Trygve
Department of Medicine, Stord Hospital, Stord, Norway.
Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Neurogastroenterol Motil. 2022 Jan;34(1):e14200. doi: 10.1111/nmo.14200. Epub 2021 Jun 18.
We recently found fecal microbiota transplantation (FMT) in irritable bowel syndrome (IBS) patients to be an effective and safe treatment after 3 months. The present follow-up study investigated the efficacy and safety of FMT at 1 year after treatment.
This study included 77 of the 91 IBS patients who had responded to FMT in our previous study. Patients provided a fecal sample and completed five questionnaires to assess their symptoms and quality of life at 1 year after FMT. The dysbiosis index (DI) and fecal bacterial profile were analyzed using a 16S rRNA gene-based DNA probe hybridization. The levels of fecal short-chain fatty acids (SCFAs) were determined by gas chromatography.
There was a persistent response to FMT at 1 year after treatment in 32 (86.5%) and 35 (87.5%) patients who received 30-g and 60-g FMT, respectively. In the 30-g FMT group, 12 (32.4%) and 8 (21.6%) patients showed complete remission at 1 year and 3 months, respectively; the corresponding numbers in the 60-g FMT group were 18 (45%) and 11 (27.5%), respectively. Abdominal symptoms and the quality of life were improved at 1 year compared with after 3 months. These findings were accompanied by comprehensive changes in the fecal bacterial profile and SCFAs.
Most of the IBS patients maintained a response at 1 year after FMT. Moreover, the improvements in symptoms and quality of life increased over time. Changes in DI, fecal bacterial profile and SCFAs were more comprehensive at 1 year than after 3 months. www.clinicaltrials.gov (NCT03822299).
我们最近发现，对肠易激综合征（IBS）患者进行粪便微生物群移植（FMT）在3个月后是一种有效且安全的治疗方法。本随访研究调查了治疗后1年FMT的疗效和安全性。
本研究纳入了我们之前研究中91例对FMT有反应的IBS患者中的77例。患者提供粪便样本，并在FMT后1年完成五份问卷，以评估其症状和生活质量。使用基于16S rRNA基因的DNA探针杂交分析失调指数（DI）和粪便细菌谱。通过气相色谱法测定粪便短链脂肪酸（SCFA）水平。
分别接受30g和60g FMT的患者中，治疗后1年有32例（86.5%）和35例（87.5%）对FMT持续有反应。在30g FMT组中，分别有12例（32.4%）和8例（21.6%）患者在1年和3个月时完全缓解；60g FMT组中的相应数字分别为18例（45%）和11例（27.5%）。与3个月后相比，1年时腹部症状和生活质量得到改善。这些发现伴随着粪便细菌谱和SCFA的全面变化。
大多数IBS患者在FMT后1年仍保持反应。此外，症状和生活质量的改善随时间增加。1年时DI、粪便细菌谱和SCFA的变化比3个月后更全面。www.clinicaltrials.gov（NCT03822299）。
